sandoz ustekinumab - Search News

Sandoz launches biosimilar Pyzchiva in U.S

Business Insider · 4d

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy

Hosted on MSN · 4d

Sandoz launches biosimilar Pyzchiva in U.S. for all approved Stelara indications

Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the U.

Pharmabiz · 3d

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge

MarketWatch · 4d

Samsung Bioepis Announces US Launch of PYZCHIVA(R) (ustekinumab-ttwe), Biosimilar to Stelara

Samsung Bioepis Co., Ltd. today announced that PYZCHIVA(R) (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been appr

J&J sues Samsung over a contract breach for a Stelara biosimilar

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

Hosted on MSN2d

J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contract

Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

3d

J&J sues Samsung Bioepis over Stelara biosimilar

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results